IFP Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

IFP Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,484	Closed	-$159K	–	4238
2018 Q1	$159K	Hold	3,484	–	–	0.01%	1103
2017 Q4	$159K	Sell	3,484 -211	-6%	-$10.5K	0.01%	1109
2017 Q3	$166K	Buy	3,695 +176	+5%	+$6K	0.01%	1258
2017 Q2	$105K	Sell	3,519 -155	-4%	-$3.83K	﹤0.01%	1504
2017 Q1	$82K	Buy	3,674 +1,811	+97%	+$38.8K	﹤0.01%	1637
2016 Q4	$35K	Sell	1,863 -4,165	-69%	-$102K	﹤0.01%	2094
2016 Q3	$181K	Sell	6,028 -2,571	-30%	-$80K	0.01%	1051
2016 Q2	$331K	Buy	+8,599	New	+$357K	0.02%	739
2016 Q1	–	Sell	-2,604	Closed	-$114K	–	3989
2015 Q4	$114K	Buy	+2,604	New	+$129K	0.01%	1111

IFP Advisors's JUNO Position: Q2 2018 in Review

IFP Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2018, closing a stake of 3,484 shares — an estimated $159K sold.

IFP Advisors first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $331K in Q2 2016. 0 funds tracked by Wall St. Rank hold JUNO as of Q2 2018.

IFP Advisors reported no remaining Juno Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
IFP Advisors sold 3,484 Juno Therapeutics, Inc. shares in Q2 2018, an estimated $159K.
IFP Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
IFP Advisors's Juno Therapeutics, Inc. position peaked at $331K in Q2 2016.
0 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2018.

Based on IFP Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.